[en] Rationale: There is a need to minimize oral corticosteroid (OCS) use in patients with asthma to prevent their costly and burdensome adverse effects. Current guidelines do not provide recommendations for OCS tapering in patients with asthma.Objectives: To develop expert consensus on OCS tapering among international experts.Methods: A modified Delphi method was used to develop expert consensus statements relating to OCS use, tapering, adverse effects, adrenal insufficiency, and patient-physician shared decision-making. Initial statements proposed by experts were categorized, filtered for repetition, and presented back to experts over three ranking rounds to obtain consensus (≥70% agreement).Measurements and Main Results: One hundred thirty-one international experts participated in the study, and 296 statements were ranked. Numerous recommendations and guidance regarding appropriate OCS use were established. Experts agreed that OCS tapering should be attempted in all patients with asthma receiving maintenance OCS therapy, with personalization of tapering rhythm and speed. The importance of recognizing individual adverse effects was also established; however, a unified approach to the assessment of adrenal insufficiency was not reached. Shared decision-making was considered an important goal during the tapering process.Conclusions: In this Delphi study, expert consensus statements were generated on OCS use, tapering, adverse-effect screening, and shared decision-making, which may be used to inform clinical practice. Areas of nonconsensus were identified, highlighting uncertainty among the experts around some aspects of OCS use in asthma, such as adrenal insufficiency, which underscores the need for further research in these domains.
Disciplines :
Immunology & infectious disease
Author, co-author :
Suehs, Carey M.
Menzies-Gow, Andrew
Price, David
Bleecker, Eugene R.
Canonica, Giorgio Walter
Gurnell, Mark
Bourdin, Arnaud
Other collaborator :
Cataldo, Didier ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Language :
English
Title :
Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study.
Publication date :
2021
Journal title :
American Journal of Respiratory and Critical Care Medicine
ISSN :
1073-449X
eISSN :
1535-4970
Publisher :
American Thoracic Society, United States - New York
Global Asthma Network. The global asthma report 2018. Auckland, New Zealand: Global Asthma Network; 2018 [accessed 2020 Sep 30] Available from: http://www.globalasthmareport.org.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373. [Published erratum appears in Eur Respir J 43:1216.]
Global Initiative for Asthma. Global strategy for asthma management and prevention. Fontana, WI: Global Initiative for Asthma; 2020 [accessed 2020 Sep 30]. Available from: https://ginasthma.org.
Canonica GW, Colombo GL, Bruno GM, Di Matteo S, Martinotti C, Blasi F, et al.; SANI Network. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J 2019;12:100007.
Ekström M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden. Allergy 2019;74:2181-2190.
Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med 2017;17:74.
Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int 2020;69: 53-60.
Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001;(1):CD002178.
Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al.; The FACET International Study Group. Exacerbations of asthma: A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999;160:594-599.
Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med 2020;201: 276-293.
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: Long-term observational study. J Asthma Allergy 2018;11: 193-204.
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.
Lee H, Ryu J, Nam E, Chung SJ, Yeo Y, Park DW, et al. Increased mortality in patients with corticosteroid-dependent asthma: A nationwide population-based study. Eur Respir J 2019;54: 1900804.
Hyland ME, Whalley B, Jones RC, Masoli M. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. Qual Life Res 2015;24:631-639.
Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: A narrative review. Respirology 2020;25: 161-172.
McBrien CN, Menzies-Gow A. Time to FOCUS on oral corticosteroid stewardship in asthma management. Respirology 2019;24: 304-305.
Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, et al. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics. Clin Exp Allergy 2020;50:442-452.
Cameron SJ, Cooper EJ, Crompton GK, Hoare MV, Grant IW. Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma. BMJ 1973;4:205-207.
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al.; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371: 1189-1197.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al.; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017;376:2448-2458.
Vogelmeier C, Kardos P, Hofmann T, Canisius S, Scheuch G, Muellinger B, et al. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. Eur Respir J 2015;45: 1273-1282.
Braunstahl G-J, Chlumský J, Peachey G, Chen C-W. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol 2013; 9:47.
Lacronique J, Renon D, Georges D, Henry-Amar M, Marsac J. High-dose beclomethasone: Oral steroid-sparing effect in severe asthmatic patients. Eur Respir J 1991;4:807-812.
Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al.; rhuMAb-E25 Study Group. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341: 1966-1973.
Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res 2019;5:00009-2019.
Chipps BE, Bacharier LB, Murphy KR, Lang D, Farrar JR, Rank M, et al. The asthma controller step-down yardstick. Ann Allergy Asthma Immunol 2019;122:241-262, e4.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020 [accessed 2020 Sep 30]. Available from: https://www.R-project.org/.
Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med 1990; 112:577-581.
Nelson HS, Busse WW, deBoisblanc BP, Berger WE, Noonan MJ, Webb DR, et al. Fluticasone propionate powder: Oral corticosteroidsparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103:267-275.
Chlumský J, Striz I, Terl M, Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006;34:129-139.
Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002;360:1715-1721.
Jayaram L, Pizzichini MM, Cook RJ, Boulet L-P, Lemière C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations. Eur Respir J 2006;27:483-494.
Hashimoto S, Brinke AT, Roldaan AC, van Veen IH, Möller GM, Sont JK, et al. Internet-based tapering of oral corticosteroids in severe asthma: A pragmatic randomised controlled trial. Thorax 2011;66: 514-520.
Bourdin A, Adcock I, Berger P, Bonniaud P, Chanson P, Chenivesse C, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev 2020;29:190085.
Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study. BMJ 2017;357:j1415.
Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J 2017;50:1701782.
Pisani P, Renna MD, Conversano F, Casciaro E, Muratore M, Quarta E, et al. Screening and early diagnosis of osteoporosis through Xray and ultrasound based techniques. World J Radiol 2013;5: 398-410.
Mortimer KJ, Tata LJ, Smith CJP, West J, Harrison TW, Tattersfield AE, et al. Oral and inhaled corticosteroids and adrenal insufficiency: A case-control study. Thorax 2006;61:405-408.
Iqbal K, Halsby K, Murray RD, Carroll PV, Petermann R. Glucocorticoid management of adrenal insufficiency in the United Kingdom: Assessment using real-world data. Endocr Connect 2019;8:20-31.
Williams EL, Choudhury S, Tan T, Meeran K. Prednisolone replacement therapy mimics the circadian rhythm more closely than other glucocorticoids. J Appl Lab Med 2016;1:152-161.
Quinkler M, Ekman B, Marelli C, Uddin S, Zelissen P, Murray RD; EUAIR Investigators. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect 2017;6:1-8.
Meeran K. Hydrocortisone vs prednisolone in AI (HYPER-AID). Bethesda, MD: ClinicalTrials.gov, U.S. National Library of Medicine; 2019 [accessed 2020 Sep 30]. Available from: https://clinicaltrials. gov/ct2/show/NCT03608943.
Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol 2019;122:463-470.
Tapp H, Shade L, Mahabaleshwarkar R, Taylor YJ, Ludden T, Dulin MF. Results from a pragmatic prospective cohort study: Shared decision making improves outcomes for children with asthma. J Asthma 2017;54:392-402.
Fiks AG, Mayne SL, Karavite DJ, Suh A, O'Hara R, Localio AR, et al. Parent-reported outcomes of a shared decision-making portal in asthma: A practice-based RCT. Pediatrics 2015;135: E965-e973.
Gargon E, Crew R, Burnside G, Williamson PR. Higher number of items associated with significantly lower response rates in COS Delphi surveys. J Clin Epidemiol 2019;108:110-120.
